Dudediligence.

Alzamend Neuro, Inc

ALZNNASDAQ · Pharmaceutical Preparations
Write an idea

Fundamentals

Oldest to newest
Net income, by quarter
−$1.4MOct ’24−$1.0MJan ’25−$1.1MApr ’25−$2.7MJul ’25−$1.0MOct ’25−$2.2MJan ’26−$2.9MApr ’26−$3.0MJul ’26
Fiscal years, by the month each ended
LineApr 2022Apr 2023Apr 2024Apr 2025Apr 2026
Operating income−$12.3M−$14.9M−$9.9M−$4.5M−$8.8M
Net income−$12.4M−$14.9M−$9.9M−$4.5M−$8.8M
Operating cash flow−$6.6M−$8.9M−$8.3M−$6.6M−$8.1M
Cash$14.1M$5.1M$376,048$3.9M$710,689
Shares outstanding95.5M646.3K76.4K778.7K4.3M